sur ABIVAX (EPA:ABVX)
Abivax to Present Data on Obefazimod at Digestive Disease Week®
Abivax SA is set to present nine scientific abstracts on its lead drug candidate, obefazimod, at the 2026 Digestive Disease Week (DDW) in Chicago. This event will take place from May 2-5, 2026. The presentations cover comprehensive data from the Phase 3 ABTECT program, focusing on its efficacy and safety in treating moderately to severely active ulcerative colitis (UC).
According to Fabio Cataldi, MD, Chief Medical Officer, the data showcases obefazimod's potential to improve patient outcomes. The abstracts detail significant findings such as histologic and endoscopic improvements and patient-reported benefits in fatigue and quality of life.
Marc de Garidel, MBA, CEO of Abivax, highlighted that these findings reflect the strength of the obefazimod dataset. They aim to provide meaningful innovations for patients with ulcerative colitis.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX